Literature DB >> 10914547

Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.

C Wuchter1, J Harbott, C Schoch, S Schnittger, A Borkhardt, L Karawajew, R Ratei, V Ruppert, T Haferlach, U Creutzig, B Dörken, W D Ludwig.   

Abstract

Translocations involving 11q23 are among the most common genetic abnormalities in hematologic malignancies, occurring in approximately 5-10% of acute lymphoblastic leukemia (ALL) and 5% of acute myeloblastic leukemia (AML). In 11q23 translocations, the mixed lineage leukemia (MLL) gene on chromosome 11, band q23, is usually disrupted. The human homologue of the rat NG2 chondroitin sulfate proteoglycan molecule, as detected by the monoclonal antibody (moab) 7.1, was shown to be expressed on leukemic cells with MLL rearrangements of children with acute leukemia. We further investigated the reactivity of the moab 7.1 on 533 cell samples of adults (n = 215) and children (n = 318) with acute leukemias (271 AML, 217 B-lineage ALL, 37 T-lineage ALL, eight CD7+ CD56+ myeloid/natural killer cell precursor acute leukemias) by flow cytometry. In AML, 38 samples were positive for moab 7.1 ('20%-cut-off-level'). These moab 7.1-positive AML cases revealed a myelomonocytic-differentiated immunophenotype with coexpression of the NK cell marker CD56 in 33 of 38 cases. Two of eight cell samples of the recently described CD7+ CD56+ myeloid/natural killer cell precursor acute leukemia entity reacted with moab 7.1. In ALL, 35 samples mostly of the pro-B-ALL subtype (33 pro-B-ALL, one common-ALL, one pre-B-ALL) were positive for moab 7.1. 58 (81%) of 72 samples with MLL rearrangements were positive for moab 7.1 including 28/31 with a t(4;11), 16/17 with a t(9;11), 3/5 with a t(11;19), and 2/6 with a del(11)(q23). All moab 7.1-positive ALL (n = 34) and childhood AML (n = 17) cases revealed MLL rearrangements as detected by Southern blot analysis and RT-PCR. However, 11 adults with AML, and one adult with moab 7.1-positive CD7+ CD56+ myeloid/natural killer cell precursor acute leukemia were negative for MLL rearrangements as proved by Southern blot analysis. We conclude that moab 7.1 is a sensitive but not entirely specific marker for the identification of 11q23-associated AML and ALL by flow cytometry in children and adults.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914547     DOI: 10.1038/sj.leu.2401840

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

1.  Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Authors:  Brunangelo Falini; Maria Paola Martelli; Stefano A Pileri; Cristina Mecucci
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

Review 2.  Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review.

Authors:  Yan Ma; Bobin Chen; Xiaoping Xu; Guowei Lin
Journal:  Int J Hematol       Date:  2009-07-30       Impact factor: 2.490

Review 3.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

4.  A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.

Authors:  Ingo Schubert; Christian Kellner; Christoph Stein; Markus Kügler; Michael Schwenkert; Domenica Saul; Kristin Mentz; Heiko Singer; Bernhard Stockmeyer; Wolfgang Hillen; Andreas Mackensen; Georg H Fey
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

5.  Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.

Authors:  Bruno A Lopes; Caroline Pires Poubel; Cristiane Esteves Teixeira; Aurélie Caye-Eude; Hélène Cavé; Claus Meyer; Rolf Marschalek; Mariana Boroni; Mariana Emerenciano
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

6.  MLL-ENL cooperates with SCF to transform primary avian multipotent cells.

Authors:  Cathleen E Schulte; Marieke von Lindern; Peter Steinlein; Hartmut Beug; Leanne M Wiedemann
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

7.  Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies.

Authors:  Allison S Drake; Michael T Brady; Xin Hui Wang; Sheila J N Sait; Justin C Earp; Sampa Ghoshal Gupta; Soldano Ferrone; Eunice S Wang; Meir Wetzler
Journal:  Cancer Immunol Immunother       Date:  2008-08-02       Impact factor: 6.968

8.  Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.

Authors:  M Bardini; P S Woll; L Corral; S Luc; L Wittmann; Z Ma; L Lo Nigro; G Basso; A Biondi; G Cazzaniga; S E W Jacobsen
Journal:  Leukemia       Date:  2014-05-06       Impact factor: 11.528

Review 9.  In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  Mol Cancer Ther       Date:  2021-04-26       Impact factor: 6.009

10.  A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Authors:  Michael Schwenkert; Katrin Birkholz; Michael Schwemmlein; Christian Kellner; Markus Kügler; Matthias Peipp; Dirk M Nettelbeck; Beatrice Schuler-Thurner; Niels Schaft; Jan Dörrie; Soldano Ferrone; Eckhart Kämpgen; Georg H Fey
Journal:  Melanoma Res       Date:  2008-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.